《CSCO免疫检查点抑制剂相关的毒性管理指南》解读:对比NCCN免疫治疗相关毒性管理指南  

Comments on CSCO management guideline of toxicities from immune checkpoint inhibitors:comparing with NCCN guideline

作　　者：赵静[1] 苏春霞[1] Zhao Jing;Su Chunxia(Department of Medical Oncology,Shanghai Pulmonary Hospital,Tongji University School of Medicine,Shanghai 200433)

机构地区：[1]同济大学附属上海市肺科医院肿瘤科,上海200433

出　　处：《实用肿瘤杂志》2020年第1期11-15,共5页Journal of Practical Oncology

摘　　要：随着免疫检查点抑制剂在肿瘤治疗中的应用日益广泛,其不良反应管理的必要性和重要性日益凸显。2018年,美国国家综合癌症网络(National Comprehensive Cancer Network,NCCN)发表《免疫治疗相关毒性的管理指南》,系统介绍和讨论不良反应的管理流程。随着国产免疫治疗药物相继进入临床,保障临床应用的规范化和安全性显得刻不容缓,中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)于2019年4月推出首部《CSCO免疫检查点抑制剂相关的毒性管理指南》。本解读将简要介绍CSCO指南的内容,并对比其与NCCN指南的差异,以期为不良反应的管理带来更深层次的理解。Immune checkpoint inhibitors(ICIs)have been used in an increasing number of cancer patients,so that the management of immune related toxicities has become more and more necessary and important.In 2008,National Comprehensive Cancer Network(NCCN)published management guideline of toxicities from immunotherapy,in which detailed strategies have been recommended for toxicity diagnosis and management.With the development and use of Chinese ICIs,it has become urgent to guarantee the standardization and safety of clinical application.In April 2019,Chinese Society of Clinical Oncology(CSCO)developed CSCO management guideline of toxicities from immune checkpoint inhibitors.Here,we will introduce the CSCO guideline briefly and compare these two guidelines,hoping to get a thorough and in-depth understanding of managing immune-related toxicities.

关 键 词：肿瘤/治疗 程序性细胞死亡受体1 免疫疗法 抗体 单克隆/治疗应用 药物相关性副作用和不良反应 药物疗法管理 中国 诊疗准则 指南 

分 类 号：R73[医药卫生—肿瘤] R730.5[医药卫生—临床医学]